BSX · 10-Q · 2026Q2 · Full report

Operating Cash Flow and Capex

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 69 · Surprise 64

Operating cash flow was $1.822 billion in the first six months of 2026, broadly unchanged from $1.827 billion in the prior-year period. Higher sales and operating income were offset by increased employee-related and working-capital payments. Investing cash outflows increased to $2.547 billion from $1.626 billion, including $372 million of property, plant and equipment and internal-use software purchases versus $344 million in 2025. Financing cash outflows were $670 million and included $1.675 billion of commercial-paper proceeds, the $2.0 billion share repurchase and repayment of $255 million of 3.750% Senior Notes.

Key facts

• For the six months ended June 30, 2026, cash provided by operating activities was $1,822 million, cash used for investing activities was $(2,547) million, and cash used for financing activities was $(670) million. source
• During the first six months of 2026, cash used for investing activities included purchases of property, plant and equipment and internal use software of $372 million. source